The Essential Reproductive Hormone: Pregnant Mare Serum Gonadotropin (PMSG) API Market Dynamics, Bio
公開 2026/03/27 17:35
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Pregnant Mare Serum Gonadotropin (PMSG) API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pregnant Mare Serum Gonadotropin (PMSG) API market, including market size, share, demand, industry development status, and forecasts for the next few years.
For livestock producers, veterinary pharmaceutical manufacturers, and animal reproduction specialists, achieving optimal reproductive outcomes in breeding programs is essential to productivity, genetic improvement, and operational efficiency. The success of artificial insemination, embryo transfer, and estrus synchronization protocols depends critically on the availability of standardized, high-activity reproductive hormones that reliably stimulate follicle development and ovulation. Pregnant mare serum gonadotropin (PMSG) API addresses this requirement as a glycoprotein hormone extracted from the serum of pregnant mares, exhibiting both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activities. Widely used in veterinary medicine to induce estrus, stimulate ovulation, and enhance fertility in livestock species, PMSG serves as the essential raw material for reproductive veterinary formulations, obtained through biological extraction, purification, and lyophilization processes that preserve its bioactivity and ensure stability. The global market for PMSG API was valued at US$ 134 million in 2025 and is projected to grow at a CAGR of 4.6% to reach US$ 183 million by 2032, driven by increasing demand for efficient livestock reproduction, expansion of artificial insemination programs, and growth in veterinary pharmaceutical applications. In 2024, global production reached approximately 45.25 billion IU, with an average market price of US$ 2.8 per 1,000 IU.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096843/pregnant-mare-serum-gonadotropin--pmsg--api
Market Definition and Product Segmentation
PMSG API represents a specialized category within the veterinary pharmaceutical ingredient market, distinguished by its dual FSH and LH biological activity that enables comprehensive reproductive hormone support. This API is extracted from pregnant mare serum, purified, and processed to maintain the specific glycoprotein structure essential for its bioactivity, serving as the core active component that determines the efficacy and consistency of finished reproductive hormone products.
Potency Type Segmentation
The market is stratified by biological activity concentration, each addressing distinct formulation and application requirements:
1000 IU/mg: The established segment, offering lower potency suitable for formulations requiring precise dosage control and for applications where lower concentrations are clinically appropriate.
5000 IU/mg: The higher-potency segment, providing concentrated activity for formulations requiring smaller volumes or higher dosing, preferred for certain production-scale applications.
Others: Including intermediate potencies for specialized formulations.
Application Segmentation
The market serves diverse livestock sectors:
Pigs: The largest segment, supporting artificial insemination programs, estrus synchronization, and reproductive management in swine production where PMSG is widely used to induce ovulation and synchronize estrus.
Cattle: Serving dairy and beef cattle operations where reproductive efficiency directly impacts milk production, calf crop, and genetic improvement, with PMSG used for superovulation and synchronization protocols.
Sheep: Supporting breeding programs in sheep operations, including synchronization for artificial insemination and embryo transfer.
Horses: Serving equine reproduction, where PMSG is used in breeding management protocols.
Other Animals: Including goats and specialized research applications.
Competitive Landscape
The PMSG API market features a competitive landscape dominated by specialized manufacturers with expertise in biological extraction, purification, and stabilization. Key players include Ísteka ehf, Syntex SA, Ningbo Sansheng Biological Technology, Ningbo Second Hormone Factory, Chifeng Bo-en Pharmaceutical, Guangzhou Vbio-Pharma, and Xiamen ORIGIN BIOTECH.
Industry Development Characteristics
1. Dual Hormone Activity Advantage
A case study from QYResearch's industry monitoring reveals that PMSG's dual FSH and LH activity makes it uniquely effective for reproductive management. The FSH-like activity stimulates follicle development, while LH-like activity promotes ovulation—combining both functions in a single API simplifies formulation and reduces the number of products required for comprehensive reproductive protocols.
2. Artificial Insemination Program Expansion
The global expansion of artificial insemination (AI) programs—particularly in dairy cattle, swine, and equine operations—has increased demand for PMSG API. A case study from the livestock sector indicates that AI programs rely on PMSG for estrus synchronization and superovulation protocols, with API quality directly impacting program success rates and overall reproductive efficiency.
3. Purification and Stabilization Technology
Advances in purification and stabilization technologies have improved API consistency and shelf life. A case study from the pharmaceutical manufacturing sector indicates that modern purification processes reduce batch-to-batch variability, while lyophilization and stabilization techniques extend product stability, enabling global distribution and consistent clinical performance.
4. Source Material Dependency
The production of PMSG API depends on the availability of high-quality pregnant mare serum. A case study from the manufacturing sector indicates that manufacturers with established supply chains, controlled collection processes, and consistent purification capabilities capture competitive advantage in delivering API with reliable, reproducible biological activity.
Exclusive Industry Insights: The Biological Activity Standardization
Our proprietary analysis identifies standardization of biological activity as the critical quality parameter for PMSG API. Unlike chemically synthesized pharmaceuticals where purity can be measured by mass, biological APIs require activity-based standardization to ensure consistent clinical performance. Manufacturers that maintain rigorous bioassay protocols, documented activity profiles, and batch-to-batch consistency capture preference from veterinary pharmaceutical companies seeking reliable, predictable API.
Strategic Outlook
For industry executives, investors, and marketing leaders evaluating opportunities in the PMSG API market, the projected 4.6% CAGR reflects sustained demand from livestock reproduction efficiency, AI program expansion, and veterinary pharmaceutical growth. Manufacturers positioned to capture disproportionate share share three characteristics: demonstrated expertise in biological extraction, purification, and stabilization; product portfolios spanning multiple potency levels; and established relationships with veterinary pharmaceutical manufacturers, livestock producers, and animal reproduction specialists. As the market evolves toward higher purity standards, enhanced stability, and expanded applications in assisted reproduction, the ability to deliver consistent, high-activity PMSG API will define competitive leadership.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For livestock producers, veterinary pharmaceutical manufacturers, and animal reproduction specialists, achieving optimal reproductive outcomes in breeding programs is essential to productivity, genetic improvement, and operational efficiency. The success of artificial insemination, embryo transfer, and estrus synchronization protocols depends critically on the availability of standardized, high-activity reproductive hormones that reliably stimulate follicle development and ovulation. Pregnant mare serum gonadotropin (PMSG) API addresses this requirement as a glycoprotein hormone extracted from the serum of pregnant mares, exhibiting both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activities. Widely used in veterinary medicine to induce estrus, stimulate ovulation, and enhance fertility in livestock species, PMSG serves as the essential raw material for reproductive veterinary formulations, obtained through biological extraction, purification, and lyophilization processes that preserve its bioactivity and ensure stability. The global market for PMSG API was valued at US$ 134 million in 2025 and is projected to grow at a CAGR of 4.6% to reach US$ 183 million by 2032, driven by increasing demand for efficient livestock reproduction, expansion of artificial insemination programs, and growth in veterinary pharmaceutical applications. In 2024, global production reached approximately 45.25 billion IU, with an average market price of US$ 2.8 per 1,000 IU.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096843/pregnant-mare-serum-gonadotropin--pmsg--api
Market Definition and Product Segmentation
PMSG API represents a specialized category within the veterinary pharmaceutical ingredient market, distinguished by its dual FSH and LH biological activity that enables comprehensive reproductive hormone support. This API is extracted from pregnant mare serum, purified, and processed to maintain the specific glycoprotein structure essential for its bioactivity, serving as the core active component that determines the efficacy and consistency of finished reproductive hormone products.
Potency Type Segmentation
The market is stratified by biological activity concentration, each addressing distinct formulation and application requirements:
1000 IU/mg: The established segment, offering lower potency suitable for formulations requiring precise dosage control and for applications where lower concentrations are clinically appropriate.
5000 IU/mg: The higher-potency segment, providing concentrated activity for formulations requiring smaller volumes or higher dosing, preferred for certain production-scale applications.
Others: Including intermediate potencies for specialized formulations.
Application Segmentation
The market serves diverse livestock sectors:
Pigs: The largest segment, supporting artificial insemination programs, estrus synchronization, and reproductive management in swine production where PMSG is widely used to induce ovulation and synchronize estrus.
Cattle: Serving dairy and beef cattle operations where reproductive efficiency directly impacts milk production, calf crop, and genetic improvement, with PMSG used for superovulation and synchronization protocols.
Sheep: Supporting breeding programs in sheep operations, including synchronization for artificial insemination and embryo transfer.
Horses: Serving equine reproduction, where PMSG is used in breeding management protocols.
Other Animals: Including goats and specialized research applications.
Competitive Landscape
The PMSG API market features a competitive landscape dominated by specialized manufacturers with expertise in biological extraction, purification, and stabilization. Key players include Ísteka ehf, Syntex SA, Ningbo Sansheng Biological Technology, Ningbo Second Hormone Factory, Chifeng Bo-en Pharmaceutical, Guangzhou Vbio-Pharma, and Xiamen ORIGIN BIOTECH.
Industry Development Characteristics
1. Dual Hormone Activity Advantage
A case study from QYResearch's industry monitoring reveals that PMSG's dual FSH and LH activity makes it uniquely effective for reproductive management. The FSH-like activity stimulates follicle development, while LH-like activity promotes ovulation—combining both functions in a single API simplifies formulation and reduces the number of products required for comprehensive reproductive protocols.
2. Artificial Insemination Program Expansion
The global expansion of artificial insemination (AI) programs—particularly in dairy cattle, swine, and equine operations—has increased demand for PMSG API. A case study from the livestock sector indicates that AI programs rely on PMSG for estrus synchronization and superovulation protocols, with API quality directly impacting program success rates and overall reproductive efficiency.
3. Purification and Stabilization Technology
Advances in purification and stabilization technologies have improved API consistency and shelf life. A case study from the pharmaceutical manufacturing sector indicates that modern purification processes reduce batch-to-batch variability, while lyophilization and stabilization techniques extend product stability, enabling global distribution and consistent clinical performance.
4. Source Material Dependency
The production of PMSG API depends on the availability of high-quality pregnant mare serum. A case study from the manufacturing sector indicates that manufacturers with established supply chains, controlled collection processes, and consistent purification capabilities capture competitive advantage in delivering API with reliable, reproducible biological activity.
Exclusive Industry Insights: The Biological Activity Standardization
Our proprietary analysis identifies standardization of biological activity as the critical quality parameter for PMSG API. Unlike chemically synthesized pharmaceuticals where purity can be measured by mass, biological APIs require activity-based standardization to ensure consistent clinical performance. Manufacturers that maintain rigorous bioassay protocols, documented activity profiles, and batch-to-batch consistency capture preference from veterinary pharmaceutical companies seeking reliable, predictable API.
Strategic Outlook
For industry executives, investors, and marketing leaders evaluating opportunities in the PMSG API market, the projected 4.6% CAGR reflects sustained demand from livestock reproduction efficiency, AI program expansion, and veterinary pharmaceutical growth. Manufacturers positioned to capture disproportionate share share three characteristics: demonstrated expertise in biological extraction, purification, and stabilization; product portfolios spanning multiple potency levels; and established relationships with veterinary pharmaceutical manufacturers, livestock producers, and animal reproduction specialists. As the market evolves toward higher purity standards, enhanced stability, and expanded applications in assisted reproduction, the ability to deliver consistent, high-activity PMSG API will define competitive leadership.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ